

# Atypical Hemolytic Uremic Syndrome in a 13-year-old Lao Girl: A Case Report

Philavanh Kedsatha, M.D.<sup>1</sup>  
Hae Il Cheong, M.D., Ph.D.<sup>2,3</sup>  
Yong Choi, M.D., Ph.D.<sup>2,4</sup>

Department of Pediatrics<sup>1</sup>, Children Hospital, Vientiane, Lao PDR,  
Department of Pediatrics<sup>2</sup>, Seoul National University Children's Hospital, Seoul, Korea, Kidney Research Institute<sup>3</sup>, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, The Lee Jong-Wook Seoul Project<sup>4</sup>

### Corresponding author:

Hae Il Cheong, M.D., Ph.D.  
Department of Pediatrics, Seoul National University Children's Hospital 101 Daehang-no, Jongno-Gu, Seoul 03080, Korea  
Tel: +82-2-2072-2810  
Fax: +82-2-743-3455  
E-mail: [cheonghi@snu.ac.kr](mailto:cheonghi@snu.ac.kr)

Received: 20 December 2018  
Revised: 15 January 2019  
Accepted: 26 January 2019

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2019 The Korean Society of Pediatric Nephrology

Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy, is distinguished from the typical form by the absence of a preceding verotoxin-producing *Escherichia coli* infection. Notably, aHUS occurs in association with genetic or acquired disorders causing dysregulation of the alternative complement pathway. Patients with aHUS may show the presence of anti-complement factor H (CFH) autoantibodies. This acquired form of aHUS (anti-CFH-aHUS) primarily affects children aged 9–13 years.

We report a case of a 13-year-old Lao girl with clinical features of aHUS (most likely anti-CFH-aHUS). The initial presentation of the patient met the classical clinical triad of thrombotic microangiopathy (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury) without preceding diarrheal illness. Low serum levels of complement 3 and normal levels of complement 4 indicated abnormal activation of the alternative complement pathway. Plasma infusion and high-dose corticosteroid therapy resulted in improvement of the renal function and hematological profile, although the patient subsequently died of infectious complications. This is the first case report that describes aHUS (possibly anti-CFH-aHUS) in Laos.

**Key words:** Atypical hemolytic uremic syndrome, Anti-complement factor H autoantibodies, Alternative complement pathway, Plasma therapy, Immunosuppression

## Introduction

Hemolytic uremic syndrome (HUS) is a prototype of thrombotic microangiopathy (TMA) and is characterized by the clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI)<sup>1</sup>. The atypical form of HUS (aHUS) is distinguished from the typical form by the absence of a prior verotoxin-producing *Escherichia coli* infection. Notably, aHUS may be classified as a primary condition or may occur secondary to bone marrow transplantation, the use of specific drugs, pneumococcal or viral infections, and autoimmune diseases<sup>1</sup>. Primary aHUS is caused by abnormal activation of the alternative complement pathway, and various kinds of genetic mutations have been reported in patients with aHUS, including mutations in the genes encoding complement factor H (CFH), complement factor I, membrane cofactor protein (MCP/CD46), complement 3 (C3), complement factor B, and thrombomodulin, among others<sup>2,3</sup>. An acquired

form of aHUS that primarily affects children aged 9–13 years is observed in those who present with aHUS in association with anti-CFH autoantibodies (anti-CFH-aHUS)<sup>4-6</sup>.

We report a case of a 13-year-old Lao girl with clinical features of aHUS, most likely anti-CFH-aHUS.

## Case report

A 13-year-old previously healthy girl reported a weight gain of 3 kg (from 48 kg to 51 kg) over 3 weeks prior to presentation with gradually increasing edema. She visited a local hospital in Vientiane, Laos PDR and underwent laboratory testing that showed the following results: hemoglobin 6.2 g/dL, platelet count 76,000 cells/mm<sup>3</sup>, serum potassium 6.9 mEq/L, blood urea nitrogen (BUN) 205 mg/dL, serum creatinine 5.5 mg/dL, serum albumin 2.9 g/dL, and serum cholesterol 289 mg/dL. Urinalysis showed 4+ proteinuria and 4+ blood. She was clinically diagnosed with nephrotic syndrome and treated with oral prednisolone (60 mg/day), enalapril, and kalimate. She also received 20% albumin infusion (100 mL/day for 3 days), transfusion of 1 unit of packed red blood cells, and furosemide infusion (20 mg/day for 2 days). Despite this management, her condition did not improve, and she was transferred to Children's Hospital, Vientiane, Laos PDR.

Upon admission, she appeared pale and edematous, although her consciousness was clear. She denied any preceding diarrheal or infectious diseases. Her family history was unremarkable without any history of renal and hematological diseases. She denied the use of any herbal medicine. Her body temperature was normal, her height and weight were higher than the 90<sup>th</sup> percentiles, systolic blood pressure varied between 120 and 140 mmHg, and her neurological status was E4V5M6 (using the Glasgow Coma Scale).

Her serum hemoglobin level was 6.7 g/dL, reticulocyte count was 3.3%, and platelet count was 103,000 cells/mm<sup>3</sup>. Serum sodium, potassium, and chloride levels were 134, 7.1, and 102 mEq/L, respectively. Serum uric acid level was 19 mg/dL. BUN and serum creatinine were 178 and 2.73 mg/dL, respectively, and serum albumin level was 3.2 g/dL. Her C3 level was 33 mg/dL (reference range 79–1.52 mg/

dL), and complement 4 level (C4) was 18 mg/dL (reference range 16–38 mg/dL). Urinalysis revealed 4+ proteinuria and 4+ blood, and the spot urine protein to creatinine ratio was 1.47 mg/mg. Antinuclear antibody, anti-double stranded DNA antibody and anti-smooth muscle antibody were negative. Her anti-streptolysin O (ASO) titer was 200 IU/mL. Direct and indirect Coombs tests showed negative results. Hepatitis B and C virus markers were negative. Renal ultrasonography revealed that the kidneys were normal in size.

She was presumptively diagnosed with rapidly progressive glomerulonephritis (RPGN) secondary to acute post-streptococcal glomerulonephritis (APSGN) and treated with intravenous methylprednisolone (30 mg/kg/day) for 3 consecutive days followed by oral prednisolone (60 mg/day). Her serum creatinine decreased to 1.91 mg/dL; however, anemia and thrombocytopenia persisted. On the 7<sup>th</sup> day of hospitalization, she developed worsening renal function (BUN and serum creatinine levels were elevated to 143 mg/dL and 5.1 mg/dL, respectively) with gradually worsening oliguria. Peripheral blood smear examination showed abundant helmet cells and a reduced platelet count, suggesting TMA (Fig. 1). Based on the absence of preceding diarrheal illness, abnormal activation of the alternative




Fig. 1. Peripheral blood smear examination showing abundant helmet cells, a reduced platelet count, and two hypersegmented neutrophils.

complement pathway, and the age of disease onset, aHUS (possibly anti-CFH-aHUS) was considered the most likely diagnosis. Therefore, a second series of methylprednisolone pulse therapy (30 mg/kg/day for 3 consecutive days) concomitant with fresh frozen plasma (FFP) infusion therapy (10 mL/kg/day for 2 consecutive days) was instituted, which improved her renal function (serum creatinine 1.4 mg/dL), anemia (hemoglobin 9.5 g/dL), thrombocytopenia (349,000 platelets/mm<sup>3</sup>), proteinuria, and oliguria. However, a few days later, her symptoms again worsened with the development of infectious diarrhea and severe pneumonia. Despite the administration of large doses of antibiotics and repeated FFP infusions, she developed severe respiratory distress with bilateral pleural effusions (requiring mechanical ventilation), uncontrolled hypertension, and severe thrombocytopenia with petechiae and purpura. She developed generalized seizures and right-sided paralysis on the 40th day of hospitalization. Her parents decided to take her home, and she died at home. The serial laboratory findings of the patient were summarized in Table 1.

## Discussion

The patient's initial clinical presentation including massive proteinuria, hematuria and azotemia indicated AKI due to glomerulonephritis. Furthermore, we suspected RPGN because of the rapid deterioration of renal function. This presentation combined with laboratory tests indicating borderline ASO titers and low C3 but normal C4 serum levels, led to a presumptive diagnosis of APSGN because this is the most common etiology in such patients. However, the occurrence of AKI, microangiopathic hemolytic

anemia, and thrombocytopenia represented the clinical triad that fulfilled the diagnostic criteria for TMA. Among the various etiologies of TMA, anti-CFH-aHUS was the most likely condition in this patient, considering the absence of preceding diarrheal illness, abnormally activated alternative complement pathway, and her age at disease onset. A partial response to initial treatment with high-dose corticosteroids also suggested the diagnosis of anti-CFH-aHUS. Unfortunately, a kidney biopsy and laboratory tests to confirm the diagnosis were unavailable in our hospital and also in our country. Following the diagnosis of aHUS (possibly anti-CFH-aHUS), high-dose corticosteroid and plasma infusion therapy improved her general condition as well as her laboratory test results, including renal function and hematological profiles. These findings strongly suggested the diagnosis of anti-CFH-aHUS. However, the patient died of infectious complications.

Approximately 50% of patients with aHUS demonstrate genetic or autoimmune abnormalities causing dysregulation of the alternative complement pathway<sup>7</sup>. *CFH* is the most commonly affected gene, and patients with *CFH* mutations comprise 20–30% of all patients with aHUS<sup>7</sup>. The presence of anti-CFH autoantibodies causes functional deficiency of CFH<sup>4–6</sup>. Anti-CFH-aHUS has been reported mainly in children aged 9–13 years, although all age groups including infants and adults may be affected<sup>6</sup>. On the other hand, the onset age of pediatric aHUS in association of genetic mutations is primarily before the age of 2 years, and onset earlier than 3 months of age is characteristic of *CFH* and *CIF* mutation-associated aHUS<sup>8</sup>. The prevalence of anti-CFH-aHUS shows ethnic differences. However, prevalence in studies reporting exclusively pediatric cases (10–56% of total cases with aHUS)<sup>2,9–11</sup> is higher than that

**Table 1. Serial Laboratory Findings of the Patient**

Laboratory data	7 days PTA	HD #1	HD #4	HD #7	HD #15	HD #22	HD #30	HD #38
Hemoglobin (g/dL)	6.2	6.7	6.4	5.0	9.5	10.9	8.2	6.5
Platelet (/mm <sup>3</sup> )	76K	103K	127K	127K	349K	96K	31K	18K
Blood urea nitrogen (mg/dL)	205	178		143		143	99	163
Serum creatinine (mg/dL)	5.5	2.73	1.91	5.1	1.4	1.9	1.87	1.73
Serum albumin (g/dL)	2.9	3.23	2.82					
Serum C3 (mg/dL)		33						
Serum C4 (mg/dL)		18						
Urine protein/creatinine (mg/mg)		1.47						

Abbreviations: PTA, prior to admission.

in studies reporting both, pediatric and adult cases (5–10%)<sup>3,11,12</sup>. A large cohort study that included patients with anti-CFH-aHUS<sup>6</sup> reported that abnormal activation of the alternative complement pathway (low serum C3 levels with normal C4 levels) was observed in 58% of the patients at disease onset, as was observed in our patient.

Interestingly, patients with anti-CFH-aHUS commonly present with severe abdominal pain and vomiting (84%) and diarrhea (53%) at disease onset<sup>6</sup>. Owing to these findings, anti-CFH-aHUS is often indistinguishable from the typical form of HUS. Additionally, extrarenal complications during the acute phase are more common than those in patients with aHUS in association with genetic mutations. The common complications are seizures in 23.5%, pancreatitis in 23.1%, and hepatitis in 50% of patients<sup>6</sup>. Our patient did not show any such extrarenal complications during the acute phase, but she developed seizures with hemiparesis later during the disease course.

The mainstay of treatment for anti-CFH-aHUS during the acute phase is early initiation of plasma exchange to remove the circulating autoantibodies and administration of corticosteroids and immunosuppressants (cyclophosphamide or rituximab) to reduce or prevent continued autoantibody production. This therapy is followed by maintenance immunosuppressant therapy (mycophenolate mofetil)<sup>13</sup>. Because plasmapheresis was unavailable in our hospital, the patient received repeated plasma transfusion instead. Although plasma infusion does not remove the circulating autoantibodies antibody, it can, at least partially, correct abnormal plasma complement profiles, which resulted from abnormal activation of the complement alternative pathway. Therefore, plasma infusion can be used as an alternative treatment for plasmapheresis when plasma exchange is unavailable or when vascular access for plasmapheresis is difficult. However, plasma infusion may result in or aggravate volume overload.

A few case reports have described that eculizumab is effective in these patients<sup>14,15</sup>; however, further studies are necessary to conclusively establish the role of eculizumab in patients with anti-CFH-aHUS. The long-term prognosis of anti-CFH-aHUS is similar to that of other forms of aHUS. Patients show a high frequency of relapse (59%), chronic kidney disease (39%), end-stage renal disease (27%), and death (9.5%)<sup>6</sup>.

In conclusion, this is the first case report that describes aHUS in Laos. A 13-year-old girl presented with microangiopathic hemolytic anemia, thrombocytopenia, and AKI without preceding diarrheal illness. Low serum levels of C3 but normal levels of C4 indicated abnormal activation of the alternative complement pathway. Treatment with plasma infusion and high-dose corticosteroid therapy, which are the best possible treatment options available in Laos, led to improvement in her renal function and hematological profile. However, she died of infectious complications. Clinicians should suspect aHUS and evaluate further in patients presenting with azotemia, anemia and thrombocytopenia without preceding diarrheal disease, although it is very rare.

## Acknowledgment

This research was supported by a grant of the Korea Health Technology Research & Development Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0013).

The Lee Jong-Wook Seoul Project is a cooperative project between the Seoul National University College of Medicine and University of Health Sciences and Lao PDR, funded by the Korean Foundation for International Healthcare.

## Conflicts of interest

The authors declare that there is potential conflict of interest.

## ORCID IDs

Philavanh Kedsatha: <https://orcid.org/0000-0003-3962-7313>

Hae Il Cheong: <https://orcid.org/0000-0001-7556-1265>

Yong Choi: <https://orcid.org/0000-0003-2287-3745>

## References

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361:1676-87.
2. Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. *Pediatr Int* 2015;57:431-8.
3. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. *Clin J Am Soc Nephrol* 2013;8:554-62.
4. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2005;16:555-63.
5. Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. *Pediatr Res* 2009;66:336-40.
6. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. *J Am Soc Nephrol* 2010;21:2180-7.
7. Chaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. *Kidney Int* 2018;94:408-18.
8. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2007;18:2392-400.
9. Inha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. *Kidney Int* 2014;85:1151-60.
10. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2013;8:407-15.
11. Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. *Kidney Int* 2017;92:1261-71.
12. Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. *Blood* 2008;111:1512-4.
13. Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. *Pediatr Nephrol* 2015;30:451-7.
14. Hisano M, Ashida A, Nakano E, Suehiro M, Yoshida Y, Matsumoto M, et al. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. *Pediatr Int* 2015;57:313-7.
15. Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. *Clin Exp Nephrol* 2015;20:265-72.